In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
US pharma major Eli Lilly on Friday announced top-line results from the LIBRETTO-431 study evaluating Retevmo (selpercatinib) versus platinum-based chemotherapy plus pemetrexed – with or without Merck & Co’s Keytruda. 7 August 2023
Pharmaceutical
The US Food and Drug Administration (FDA) approved Japanese drug major Astellas Pharma’s Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) late Friday, 7 August 2023
Biotechnology
RNA refers to a large group of biomolecules that, following their success in Covid-19 vaccines, are believed to have great medical potential for prevention and therapy - and thus also significant economic importance. 7 August 2023
Pharmaceutical
Two of the world’s largest pharmaceutical companies - Merck & Co and Pfizer - last week reported second-quarter financial results that were seriously impacted by the decline in the need for COVID-19 vaccines and treatments, but still came out with impressive figures. Troubled US biotech EQRx, which launched with the promise of reforming drug pricing, has given up its dream and accepted an all-stock merger proposal from Revolution Medicines. Japanese drugmakers Sumitomo Pharma and Otsuka suffered a setback in their two clinical trials of the schizophrenia candidate ulotaront. 6 August 2023
Biotechnology
Friday produced a mixed decision from the US Food and Drug Administration (FDA) for biotechs Sage Therapeutics and its partner Biogen regarding their new type of antidepressant. 5 August 2023
Biotechnology
Sino-American biotech specializing in liver disease and cancer Terns Pharmaceuticals has announced that Senthil Sundaram has resigned from his position as Terns’ chief executive for health reasons previously disclosed in January 2022. 5 August 2023
Pharmaceutical
US biotech Biogen announced a major M&A deal in July, with Eli Lilly and Novartis the other big biopharma companies to unveil acquisitions during the month. 4 August 2023
Biotechnology
Australian regenerative medicine company Mesoblast saw its shares plunge almost 57% to A$0.47 after it revealed a second setback in the development of it remestemcel-L. 4 August 2023
Biotechnology
Privately-held UK biotech Evox Therapeutics has announced a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) in New York, USA. 4 August 2023
Biotechnology
Ryvu Therapeutics has finalized two important agreements with Fortrea, with the news edging the Polish biotech’s shares up 1.7% to 60.00 zloty by mid-afternoon. 4 August 2023
Biotechnology
US biotech major Amgen has announced financial results for the second quarter of 2023. 4 August 2023
Biotechnology
Like other pharma majors that achieved huge sales and profits at the height of related to the COVID-19 pandemic, which has since subsided, pioneering US mRNA company Moderna reported a massive decline in second-quarter 2023 revenues. 4 August 2023
Biotechnology
US biotech major Gilead Sciences late yesterday announced results of operations for the second quarter of 2023, reducing the range for its earnings outlook after posting mixed results for the three months, but its shares managed a small initial 1.2% rise. 4 August 2023
Biotechnology
Agios Pharmaceuticals has signed exclusive worldwide license agreement with fellow USA-based Alnylam Pharmaceuticals to acquire the rights to develop and commercialize Alnylam’s novel pre-clinical siRNA targeting TMPRSS6, as a potential disease-modifying treatment for patients with polycythemia vera (PV). 4 August 2023
Biotechnology
UK drugmaker GSK is suing Pfizer to add further intensity to the race to grab the lion’s share of the respiratory syncytial virus (RSV) vaccine market. 3 August 2023
Pharmaceutical
Privately-held German drugmaker Boehringer Ingelheim has announced its financial results for the first half of 2023. 3 August 2023
Biotechnology
US autoimmune drug developer Kyverna Therapeutics today announced the close of an oversubscribed $60 million Series B financing round extension, bringing the total Series B financing round to $145 million. 3 August 2023
article
US biotech Regeneron Pharmaceuticals today announced financial results for the second quarter of 2023 and provided a business update that pleased investors and sent the firm’s up 4.2% to $769.81 in early market activity. 3 August 2023
Pharmaceutical
Life sciences company Merck KGaA revealed declining sales and profits in its latest quarterly sales figures, but the sums still exceeded the expectations of analysts. 3 August 2023
Biotechnology
German pharma major Bayer’s independently-operated subsidiary BlueRock Therapeutics has entered into a collaboration and option agreement with machine learning-powered bit.bio for the discovery and manufacture of iPSC-derived regulatory T cells (Tregs) for use in creating therapeutics. 3 August 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze